Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
41.65
+0.46 (1.12%)
May 7, 2026, 11:28 AM EDT - Market open
Veracyte Revenue
Veracyte had revenue of $139.07M in the quarter ending March 31, 2026, with 21.49% growth. This brings the company's revenue in the last twelve months to $541.74M, up 16.91% year-over-year. In the year 2025, Veracyte had annual revenue of $517.15M with 16.01% growth.
Revenue (ttm)
$541.74M
Revenue Growth
+16.91%
P/S Ratio
6.07
Revenue / Employee
$717,540
Employees
755
Market Cap
3.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 517.15M | 71.38M | 16.01% |
| Dec 31, 2024 | 445.76M | 84.71M | 23.46% |
| Dec 31, 2023 | 361.05M | 64.52M | 21.76% |
| Dec 31, 2022 | 296.54M | 77.02M | 35.09% |
| Dec 31, 2021 | 219.51M | 102.03M | 86.85% |
| Dec 31, 2020 | 117.48M | -2.89M | -2.40% |
| Dec 31, 2019 | 120.37M | 28.36M | 30.82% |
| Dec 31, 2018 | 92.01M | 20.06M | 27.87% |
| Dec 31, 2017 | 71.95M | 6.87M | 10.55% |
| Dec 31, 2016 | 65.09M | 15.58M | 31.48% |
| Dec 31, 2015 | 49.50M | 11.31M | 29.62% |
| Dec 31, 2014 | 38.19M | 16.31M | 74.51% |
| Dec 31, 2013 | 21.88M | 10.26M | 88.20% |
| Dec 31, 2012 | 11.63M | 8.98M | 339.62% |
| Dec 31, 2011 | 2.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ICON Public Limited Company | 8.10B |
| Charles River Laboratories International | 4.02B |
| Qiagen | 2.09B |
| RadNet | 2.04B |
| Sotera Health Company | 1.19B |
| NeoGenomics | 745.97M |
| CareDx | 412.82M |
| Twist Bioscience | 409.48M |
VCYT News
- 8 hours ago - Veracyte price target raised to $42 from $40 at Canaccord - TheFly
- 11 hours ago - Veracyte price target raised to $52 from $48 at UBS - TheFly
- 1 day ago - Veracyte Earnings Call Transcript: Q1 2026 - Transcripts
- 1 day ago - Veracyte Announces First Quarter 2026 Financial Results - Business Wire
- 9 days ago - Veracyte announces new data at AUA 2026 on Decipher portfolio - TheFly
- 9 days ago - Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers - Business Wire
- 17 days ago - Veracyte price target lowered to $40 from $43 at Canaccord - TheFly
- 22 days ago - Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026 - Business Wire